Trade DOCMORRIS AG ORD - DOCM CFD

Trading Conditions

• Spread: 0.65
• Long position overnight feeLong position overnight feeMargin. Your investmentCHF 1,000.00Overnight feeCharges from full value of position-0.014959 %(-CHF 0.60)Trade size with leverage ~ CHF 5,000.00Short position overnight fee ~ CHF 4,000.00Go to platform: -0.014959%
• Short position overnight feeShort position overnight feeMargin. Your investmentCHF 1,000.00Overnight feeCharges from full value of position-0.007263 %(-CHF 0.29)Trade size with leverage ~ CHF 5,000.00Short position overnight fee ~ CHF 4,000.00Go to platform: -0.007263%
• Overnight fee time: 21:00 (UTC)
• Currency: CHF
• Min traded quantity: 1
• Margin: 20
• Stock exchange: Switzerland
• Commission on trade: 0%

• Margin. Your investment: CHF 1,000.00
• Overnight feeCharges from full value of position: -0.014959 %
  (-CHF 0.60)

• Margin. Your investment: CHF 1,000.00
• Overnight feeCharges from full value of position: -0.007263 %
  (-CHF 0.29)

Key Stats

• Prev. Close: 82.45
• Open: 83.4
• 1-Year Change: 120.93%
• Day's Range: 82.3 - 84.95

ZUR ROSE GROUP N Company profile

About Zur Rose Group AG

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Zur Rose Group AG revenues increased 17% to SF1.73B. Net loss increased 66% to SF225.7M. Revenues reflect Germany segment increase of 25% to SF1.02B, Switzerland segment increase of 5% to SF620.2M, Germany segment increase of 25% to SF1.02B, Switzerland segment increase of 5% to SF620.2M. Higher net loss reflects Marketing and acquisition expenses increase of 96% to SF118.8M (expense).

Equity composition

11/2018 rights issue, adj. fct. 1.05607, new shares offered 2665476 (late adjustment from e-mail)